Cochrane · systematic review · CD012206
Non‐surgical therapies for Peyronie's disease
Rosenberg, JE, Ergun, O, Hwang, EC, et al. · Cochrane Database of Systematic Reviews · 2023 · Cochrane Library
UrologyAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
60
current version
GRADE rated
29
No studies
31
Included studies
NR
No studies 31 · 51.7%Ungraded 0 · 0%Very low 21 · 35%Low 5 · 8.3%Moderate 3 · 5%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Potassium paraaminobenzoate compared to placebo for Peyronie's disease (short‐term)
Population: men with acute (maximum of 12 months) Peyronie's disease with no prior treatment and no evidence of calcified plaques (pain during erection: 39 (37%) patients)
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Outcomes ( Potassium paraaminobenzoate vs placebo | no estimate extracted | NR | No studies |
Patient‐reported ability to have intercourse Potassium paraaminobenzoate vs placebo | RR 1.19 [0.87, 1.62] | 1 study · 75 participants | Low Downgraded: risk of bias |
Quality of life Potassium paraaminobenzoate vs placebo | no estimate extracted | NR | No studies |
Treatment‐related adverse effects Potassium paraaminobenzoate vs placebo | RR 1.27 [0.36, 4.48] | 1 study · 103 participants | Very low Downgraded: risk of bias |
Degree of penile curvature Potassium paraaminobenzoate vs placebo | no estimate extracted | NR | No studies |
Discontinuation from treatment Potassium paraaminobenzoate vs placebo | RR 1.36 [0.72, 2.58] | 1 study · 103 participants | Very low Downgraded: risk of bias |
Injectional interferon alpha‐2B compared to saline for Peyronie's disease (short‐term)
Population: men with chronic (≥ 12 months) Peyronie's disease (single plaque)
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Outcomes ( Injectional interferon alpha‐2B vs saline | no estimate extracted | NR | No studies |
Patient‐reported ability to have intercourse Injectional interferon alpha‐2B vs saline | no estimate extracted | NR | No studies |
Quality of life Injectional interferon alpha‐2B vs saline | no estimate extracted | NR | No studies |
Treatment‐related adverse effects Injectional interferon alpha‐2B vs saline | no estimate extracted | NR | No studies |
Degree of penile curvature Injectional interferon alpha‐2B vs saline | no estimate extracted | 1 study · 103 participants | Very low Downgraded: risk of bias, imprecision, indirectness |
Discontinuation from treatment Injectional interferon alpha‐2B vs saline | RR 0.63 [0.22, 1.76] | 1 study · 117 participants | Very low Downgraded: risk of bias, imprecision, indirectness |
Injectional nicardipine compared to saline for Peyronie's disease (long‐term)
Population: men with chronic Peyronie's disease (plaques without calcification)
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Outcomes ( Injectional nicardipine vs saline | no estimate extracted | NR | No studies |
Patient‐reported ability to have intercourse Injectional nicardipine vs saline | no estimate extracted | NR | No studies |
Quality of life Injectional nicardipine vs saline | no estimate extracted | NR | No studies |
Treatment‐related adverse effects Injectional nicardipine vs saline | RR 2.82 [0.12, 66.62] | 1 study · 62 participants | Very low Downgraded: risk of bias |
Degree of penile curvature Injectional nicardipine vs saline | no estimate extracted | 1 study · 62 participants | Very low Downgraded: risk of bias |
Discontinuation from treatment Injectional nicardipine vs saline | RR 0.71 [0.25, 2.05] | 1 study · 74 participants | Very low Downgraded: risk of bias |
Injectional betamethasone compared to saline for Peyronie's disease (long‐term)
Population: men with Peyronie's disease (not defined)
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Outcomes ( Injectional betamethasone vs saline | no estimate extracted | NR | No studies |
Patient‐reported ability to have intercourse Injectional betamethasone vs saline | no estimate extracted | NR | No studies |
Quality of life Injectional betamethasone vs saline | no estimate extracted | NR | No studies |
Treatment‐related adverse effects (long‐term) Injectional betamethasone vs saline | no estimate extracted | 1 study · 30 participants | Very low Downgraded: risk of bias |
Degree of penile curvature Injectional betamethasone vs saline | no estimate extracted | NR | No studies |
Discontinuation from treatment Injectional betamethasone vs saline | no estimate extracted | 1 study · 30 participants | Very low Downgraded: risk of bias |
Injectional collagenase compared to placebo for Peyronie's disease (short‐term)
Population: men with Peyronie's disease (diagnosis of disease: at least 12 months, penile curvature: at least 30 degrees)
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Outcomes ( Injectional collagenase vs placebo | no estimate extracted | NR | No studies |
Patient‐reported ability to have intercourse Injectional collagenase vs placebo | no estimate extracted | NR | No studies |
Quality of life Injectional collagenase vs placebo | no estimate extracted | 1 study · 134 participants | Low Downgraded: risk of bias |
Treatment‐related adverse effects Injectional collagenase vs placebo | no estimate extracted | NR | No studies |
Degree of penile curvature Injectional collagenase vs placebo | no estimate extracted | 1 study · 136 participants | Low Downgraded: risk of bias |
Discontinuation from treatment Injectional collagenase vs placebo | no estimate extracted | NR | No studies |
Injectional collagenase compared to placebo for Peyronie's disease (long‐term)
Population: men with Peyronie's disease (diagnosis of disease: at least 12 months, penile curvature: at least 30 degrees)
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Outcomes ( Injectional collagenase vs placebo | no estimate extracted | NR | No studies |
Patient‐reported ability to have intercourse Injectional collagenase vs placebo | no estimate extracted | NR | No studies |
Quality of life Injectional collagenase vs placebo | no estimate extracted | 1 study · 612 participants | Moderate Downgraded: risk of bias |
Treatment‐related adverse effects Injectional collagenase vs placebo | RR 2.32 [1.98, 2.72] | 1 study · 832 participants | Moderate Downgraded: risk of bias |
Degree of penile curvature Injectional collagenase vs placebo | no estimate extracted | 1 study · 612 participants | Moderate Downgraded: risk of bias |
Discontinuation from treatment Injectional collagenase vs placebo | RR 1.25 [0.84, 1.86] | 1 study · 836 participants | Very low Downgraded: risk of bias |
Injectional verapamil versus saline (short‐term)
Population: men with Peyronie's disease (palpable plaque or pain)
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Outcomes ( Injectional verapamil vs saline (short‐term) | no estimate extracted | NR | No studies |
Patient‐reported ability to have intercourse Injectional verapamil vs saline (short‐term) | RR 7 [0.43, 114.7] | 1 study · 14 participants | Very low Downgraded: risk of bias |
Quality of life Injectional verapamil vs saline (short‐term) | no estimate extracted | NR | No studies |
Treatment‐related adverse effects Injectional verapamil vs saline (short‐term) | no estimate extracted | 1 study · 14 participants | Very low Downgraded: risk of bias |
Degree of penile curvature Injectional verapamil vs saline (short‐term) | no estimate extracted | 1 study · 14 participants | Very low Downgraded: risk of bias |
Discontinuation from treatment Injectional verapamil vs saline (short‐term) | no estimate extracted | NR | No studies |
Injectional Botox compared to placebo for Peyronie's disease (short‐term)
Population: men with Peyronie's disease (stable phase)
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Outcomes ( Injectional Botox vs placebo | no estimate extracted | NR | No studies |
Patient‐reported ability to have intercourse Injectional Botox vs placebo | no estimate extracted | NR | No studies |
Quality of life Injectional Botox vs placebo | no estimate extracted | 1 study · 12 participants | Very low Downgraded: risk of bias, imprecision |
Treatment‐related adverse effects Injectional Botox vs placebo | no estimate extracted | NR | No studies |
Degree of penile curvature Injectional Botox vs placebo | no estimate extracted | NR | No studies |
Discontinuation from treatment Injectional Botox vs placebo | no estimate extracted | NR | No studies |
Extracorporeal shock wave treatment (ESWT) compared to sham for Peyronie's disease (short‐term)
Population: men with Peyronie's disease (penile plaque with pain and/or curvature, diagnosis of disease: from acute (< 12 months) to chronic (> 12 months))
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Outcomes ( Extracorporeal shock wave treatment (ESWT) vs sham | no estimate extracted | NR | No studies |
Patient‐reported ability to have intercourse Extracorporeal shock wave treatment (ESWT) vs sham | RR 1.6 [0.71, 3.6] | 1 study · 26 participants | Very low Downgraded: risk of bias |
Quality of life Extracorporeal shock wave treatment (ESWT) vs sham | no estimate extracted | 2 studies · 130 participants | Low Downgraded: risk of bias |
Treatment‐related adverse effects Extracorporeal shock wave treatment (ESWT) vs sham | RR 2.73 [0.74, 10.14] | 3 studies · 166 participants | Very low Downgraded: risk of bias |
Degree of penile curvature Extracorporeal shock wave treatment (ESWT) vs sham | no estimate extracted | 3 studies · 166 participants | Low Downgraded: risk of bias |
Discontinuation from treatment Extracorporeal shock wave treatment (ESWT) vs sham | RR 0.57 [0.06, 5.65] | 4 studies · 238 participants | Very low Downgraded: risk of bias |
Penile traction therapy versus no treatment (short‐term)
Population: men with Peyronie's disease (diagnosis of disease: varying, penile curvature: at least 30 degrees)
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Outcomes ( Penile traction therapy vs no treatment (short‐term) | no estimate extracted | NR | No studies |
Patient‐reported ability to have intercourse Penile traction therapy vs no treatment (short‐term) | no estimate extracted | NR | No studies |
Quality of life Penile traction therapy vs no treatment (short‐term) | no estimate extracted | 1 study · 82 participants | Very low Downgraded: risk of bias, imprecision |
Treatment‐related adverse effects Penile traction therapy vs no treatment (short‐term) | no estimate extracted | 1 study · 90 participants | Very low Downgraded: risk of bias, imprecision |
Degree of penile curvature Penile traction therapy vs no treatment (short‐term) | no estimate extracted | 1 study · 89 participants | Very low Downgraded: risk of bias, imprecision |
Discontinuation from treatment Penile traction therapy vs no treatment (short‐term) | RR 0.86 [0.31, 2.36] | 2 studies · 182 participants | Very low Downgraded: risk of bias, imprecision |